Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.01 USD | -0.32% |
|
+3.09% | +4.14% |
Feb. 06 | Scotiabank Adjusts Bio-Techne's Price Target to $90 From $88 | MT |
Feb. 06 | KeyBanc Adjusts Bio-Techne's Price Target to $90 From $80 | MT |
Evolution of the Average Target: Bio-Techne Corporation
Evolution of the Target Price: Bio-Techne Corporation
Changes in Analyst Recommendations: Bio-Techne Corporation
Consensus | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Ecart obj. / dr | ||
---|---|---|---|---|---|---|
+15% | ||||||
+7.33% | ||||||
+20.14% | ||||||
+32.68% | ||||||
+31.42% | ||||||
+13.57% | ||||||
+78.17% | ||||||
-3.19% | ||||||
-15.29% | ||||||
+19.76% | ||||||
Average | +19.96% | |||||
Weighted average by Cap. | +19.40% |
Analysts' Consensus

Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
RBC Capital Markets | |
Baird | |
Stifel Nicolaus | |
Scotiabank | |
Citigroup | |
Argus | |
Leerink Partners | |
UBS | |
Deutsche Bank Securities | |
Stephens Inc. | |
KeyBanc Capital Markets | |
William Blair & Co. | |
SVB Securities LLC | |
Wells Fargo Securities | |
SVB Leerink |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TECH Stock
- Consensus Bio-Techne Corporation